Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Janux Therapeutics (JANX) Cash from Operations (2020 - 2025)

Historic Cash from Operations for Janux Therapeutics (JANX) over the last 6 years, with Q3 2025 value amounting to -$12.9 million.

  • Janux Therapeutics' Cash from Operations fell 47624.38% to -$12.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$70.4 million, marking a year-over-year decrease of 9037.04%. This contributed to the annual value of -$43.8 million for FY2024, which is 1336.83% up from last year.
  • Per Janux Therapeutics' latest filing, its Cash from Operations stood at -$12.9 million for Q3 2025, which was down 47624.38% from -$23.8 million recorded in Q2 2025.
  • Janux Therapeutics' Cash from Operations' 5-year high stood at $5.6 million during Q1 2021, with a 5-year trough of -$23.8 million in Q2 2025.
  • Moreover, its 5-year median value for Cash from Operations was -$11.7 million (2023), whereas its average is -$10.9 million.
  • In the last 5 years, Janux Therapeutics' Cash from Operations tumbled by 54340.09% in 2021 and then surged by 8094.63% in 2024.
  • Over the past 5 years, Janux Therapeutics' Cash from Operations (Quarter) stood at -$10.5 million in 2021, then dropped by 13.66% to -$11.9 million in 2022, then increased by 16.89% to -$9.9 million in 2023, then tumbled by 68.92% to -$16.7 million in 2024, then rose by 23.13% to -$12.9 million in 2025.
  • Its Cash from Operations stands at -$12.9 million for Q3 2025, versus -$23.8 million for Q2 2025 and -$17.0 million for Q1 2025.